CoChat
Sign Up
Cited by 97Neuroethics, Human Enhancement, Biomedical InnovationsInsurance, Mortality, Demography, Risk ManagementGenetics, Aging, and Longevity in Model Organisms

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index; none of the 5 sources its claims cite is checked for support yet.

Escape Velocity: Why the Prospect of Extreme Human Life Extension Matters Now

Open access
de Grey, Aubrey D. N. J·2004·PLoS Biology
DOI 10.1371/journal.pbio.0020187PMC PMC423155
Open this paper in CoChat — free account

Abstract

Should we be considering the social and economic ramifications of a society where life-span could be limitless?

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

de Grey argues that extreme human life extension is a near-term policy concern because repair-based rejuvenation therapies could be indefinitely extensible and, once age-specific mortality falls fast enough, produce “actuarial escape velocity.” He criticizes contemporary commentaries for underestimating the science, demography, and social urgency of anticipating robust mouse rejuvenation.

Key findings

  • The paper rejects the view that only modest life extension is possible, pointing to a SENS-style strategy of repairing age-related molecular and cellular damage across “just seven major categories of ‘rejuvenation therapy’” that is “indefinitely extensible to greater life spans without recourse to further conceptual breakthroughs.”
  • It introduces “actuarial escape velocity” (AEV): if age-specific mortality rates decline by 10% per year at all ages and this is sustained indefinitely, “the first 1000-year-old is probably only 5–10 years younger than the first 150-year-old.”
  • It predicts a pivotal laboratory milestone—“robust mouse rejuvenation,” conservatively guessed as a trebling of remaining life span in long-lived mice treated at two-thirds of normal life span—could arrive “within just ten years, given adequate and focused funding (perhaps $100 million per year).”
  • It claims that once AEV is achieved, rejuvenation research will be intense forever and will bring “the elimination of retirement benefits,” releasing wealth; it also warns that restricted access to rejuvenation therapies could “invite violence on a scale” worth avoiding.

Methods

  • This is a single-author essay/commentary, not an empirical study; it critiques the book *Coping with Methuselah* and cites prior SENS papers by de Grey and colleagues.
  • No primary data, sample, or formal analysis are reported; the argument is conceptual and uses a figure and a table to illustrate AEV and the seven repair categories.

Limitations

  • The paper itself concedes that the 10-year robust mouse rejuvenation timeframe “could be way off” and that “we don’t know how long we have”; many claims are framed as “in my opinion,” “I claim,” or “a conservative guess.”
  • Evident from the text: it is a conceptual essay with no primary data, no formal demographic or economic modeling, and no systematic review; quantitative statements such as the 10%/year mortality decline and $100 million/year funding figure are asserted rather than derived.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pbio.0020187

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 of 5 cited sources checked · 0 supported · 0 flagged

  • Interpretationreasoning

    Given the present status of the therapies listed in Table 1, there is a high probability of reaching robust mouse rejuvenation within just ten years, given adequate and focused funding (perhaps $100 million per year).

    “But given the present status of the therapies listed in Table 1, we have, in my view, a high probability of reaching the mouse life extension milestone just described (which I call ‘robust mouse rejuvenation’) within just ten years, given adequate and focused funding (perhaps $100 million per year).”
    Quote in the paperNot a substantial claim
  • Premisecitation

    Longer-lived species will show a smaller maximal proportional life-span extension in response to starvation, probably not much more than the same absolute increase seen in shorter-lived species.

    “I have recently argued (de Grey 2004), from evolutionary considerations, that longer-lived species will show a smaller maximal proportional life-span extension in response to starvation, probably not much more than the same absolute increase seen in shorter-lived species.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites de Grey 2004

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Interpretationnone given

    Later drugs that work the same way as first-generation caloric-restriction-mimetic drugs are unlikely to much exceed the life extension achieved by first-generation drugs.

    “and that it is unlikely to be much exceeded by later drugs that work the same way.”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: Lifelong restriction of caloric intake considerably extends both the healthy and total life span of nearly all species in which it has been tried, including rodents and dogs.
  • Interpretationreasoning

    If a 10% per year decline of mortality rates at all ages is achieved and sustained indefinitely, then the first 1000-year-old is probably only 5-10 years younger than the first 150-year-old.

    “Quantitatively, what this means is that if a 10% per year decline of mortality rates at all ages is achieved and sustained indefinitely, then the first 1000-year-old is probably only 5–10 years younger than the first 150-year-old.”
    Quote in the paperNot a substantial claim
  • Interpretationreasoning

    There will come an advance-probably a single laboratory result-that breaks the camel's back and forces society to abandon denial of the prospect of defeating aging, accepting that the risk of dashed hopes is outweighed by the risk of missing the AEV boat by inaction.

    “There will come an advance—probably a single laboratory result—that breaks the camel's back and forces society to abandon that denial: to accept that the risk of getting one's hopes up and seeing them dashed is now outweighed by the risk of missing the AEV boat by inaction.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim. 10
  • It may state two separate claims as one. 4

  • Probably not a substantial claim. It may be too vague to check against evidence. The paper may give no reason why it holds.

    Interpretationreasoning

    The announcement of such mice will cause huge, essentially immediate, society-wide changes in lifestyle and expenditure choices-pandemonium-resulting from the anticipation that extreme human life extension might arrive soon enough to benefit people already alive.

    “It seems quite certain to me that the announcement of such mice will cause huge, essentially immediate, society-wide changes in lifestyle and expenditure choices—in a word, pandemonium—resulting from the anticipation that extreme human life extension might arrive soon enough to benefit people already alive.”
    Quote in the paperNot a substantial claim

  • It may state two separate claims as one.

    Premisereasoning

    The remaining life expectancy of someone aged N in a given year is more than the period life expectancy minus N for two reasons: a mathematical reason and a biomedical reason (mortality rates at each age, especially advanced ages, tend to fall with time).

    “The remaining life expectancy of someone aged N in that year is more than this life expectancy minus N for two reasons: one mathematical (what one actually wants, roughly, is the age to which the probability of survival is half that of survival to N) and one biomedical (mortality rates at each age, especially advanced ages, tend to fall with time).”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Mortality rates at each age, especially advanced ages, tend to fall with time.

  • Probably not a substantial claim. It may be too vague to check against evidence. The paper may give no reason why it holds.

    Interpretationnone given

    First-generation rejuvenation therapies, whenever they arrive, will surely build on a string of prior laboratory achievements.

    “First-generation rejuvenation therapies, whenever they arrive, will surely build on a string of prior laboratory achievements.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim. It may be too vague to check against evidence. The paper may give no reason why it holds.

    Interpretationreasoning

    Even the most obvious lifestyle changes-greater expenditure on traditional medical care and avoidance of socially vital but risky professions-could severely destabilise the global economy.

    “Even the most obvious of these lifestyle changes—greater expenditure on traditional medical care, avoidance of socially vital but risky professions—could severely destabilise the global economy”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim. The paper may give no reason why it holds.

    Interpretationnone given

    A conservative guess for that advance is a trebling of the remaining life span of mice of a long-lived strain that have reached two-thirds of their normal life span before treatment begins.

    “I think a conservative guess is a trebling of the remaining life span of mice of a long-lived strain that have reached two-thirds of their normal life span before treatment begins.”
    Quote in the paperNot a substantial claim

  • It may state two separate claims as one.

    Interpretationreasoning

    Those who get first-generation therapies only just in time will be unlikely to live more than 20-30 years more than their parents, because they will spend many frail years with a short remaining life expectancy, whereas those only a little younger will never get that frail and will spend rather few years even in biological middle age.

    “those who get first-generation therapies only just in time will in fact be unlikely to live more than 20–30 years more than their parents, because they will spend many frail years with a short remaining life expectancy (i.e., a high risk of imminent death), whereas those only a little younger will never get that frail and will spend rather few years even in biological middle age.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.

    Interpretationnone given

    Overpopulation could not result for many decades.

    “Overpopulation, probably the most frequently cited drawback of curing aging, could not result for many decades”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim. It may be too vague to check against evidence. The paper may give no reason why it holds.

    Interpretationnone given

    Restricted availability of rejuvenation therapies irrespective of ability to pay, resembling that seen today with AIDS drugs, would invite violence on a scale worth trying to avoid.

    “in a post-9/11 world, restricted availability of rejuvenation therapies resembling that seen today with AIDS drugs would invite violence on a scale that, shall we say, might be worth trying to avoid.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim. It may be too vague to check against evidence. The paper may give no reason why it holds. It may state two separate claims as one.

    Interpretationnone given

    Once AEV is achieved, there will be no going back: rejuvenation research will be intense forever thereafter and will anticipate and remedy life-threatening degenerative changes appearing at newly achieved ages with ever-increasing efficacy and lead time.

    “Once AEV is achieved, there will be no going back: rejuvenation research will be intense forever thereafter and will anticipate and remedy the life-threatening degenerative changes appearing at newly achieved ages with ever-increasing efficacy and lead time.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim. It may be too vague to check against evidence.

    Premisecitation

    Big advances often occur much sooner than most experts expect.

    “as Wade notes (p. 57), big advances often occur much sooner than most experts expect.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Wade

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Probably not a substantial claim.

    Interpretationcitation

    The graph of average wealth consumed and generated by an individual as a function of age (Lee and Tuljapurkar 1997) illustrates how much wealth will be released by eliminating retirement benefits.

    “The graph just mentioned amply illustrates how much wealth will be released by this.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Lee and Tuljapurkar's (1997) source

  • Probably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.

    Interpretationnone given

    We will probably not have effective rejuvenation therapies for humans for at least 25 years, and it could certainly be 100 years.

    “We will probably not have effective rejuvenation therapies for humans for at least 25 years, and it could certainly be 100 years.”
    Quote in the paperNot a substantial claim
12 of 12

  • The paper relies on this without support.

    The seven categories of accumulating molecular or cellular side effects of metabolism are the major categories whose possible contribution to age-related mammalian physical or cognitive decline is an established school of thought within contemporary biogerontology.

    “The seven categories of accumulating molecular or cellular side effects of metabolism whose possible contribution to age-related mammalian physical or cognitive decline is an established school of thought within contemporary biogerontology”

  • The paper relies on this without support.

    Lifelong restriction of caloric intake considerably extends both the healthy and total life span of nearly all species in which it has been tried, including rodents and dogs.

    “the long-standing observation that lifelong restriction of caloric intake considerably extends both the healthy and total life span of nearly all species in which it has been tried, including rodents and dogs.”

  • The paper relies on this without support.

    Mortality rates at each age, especially advanced ages, tend to fall with time.

    “mortality rates at each age, especially advanced ages, tend to fall with time”
3 of 3

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Alzheimer, 1907, Allg Z Psychiatr Psychish-Gerichtliche Med, 64, 146

Cited by

Sorted by citations

Related

Metadata

Authors
de Grey, A. D. N. J.
Affiliations
University of Cambridge (GB)
Corresponding author
de Grey, Aubrey D. N. J
ORCID
de Grey, Aubrey D. N. J
Venue
PLoS Biology
Publisher
Public Library of Science (PLoS)
Published
2004-06-15
Volume
2
Issue
6
Pages
e187
ISSN
  • 1544-9173 (ISSN-L)
  • 1545-7885
DOI
10.1371/journal.pbio.0020187
PMC
PMC423155
OpenAlex
W2084254638
Cited by
97
References
17
Citations by year
2026: 4 · 2025: 6 · 2024: 3 · 2023: 5 · 2022: 2 · 2021: 21 · 2020: 3 · 2019: 12 · 2018: 2 · 2017: 4 · 2016: 5 · 2015: 4 · 2014: 3 · 2013: 1 · 2012: 3
FWCI
27.34
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS Biology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Social Sciences › Arts and Humanities › Philosophy › Neuroethics, Human Enhancement, Biomedical Innovations
  • Social Sciences › Demography › Insurance, Mortality, Demography, Risk Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
Keywords
lifespan extension, human lifespan, social consequences, economic implications, longevity, population growth

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review